Tregs have the potential to establish long-term immune tolerance in patients recently diagnosed with type 1 diabetes (T1D) by preserving 尾 cell function. Adoptive transfer of autologous thymic Tregs, although safe, exhibited limited efficacy in previous T1D clinical trials, likely reflecting a lack...
today announces that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease
Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64, 2172–2183 (2015). Article CAS PubMed Google Scholar Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes ...
7.Ferraro, A., et al., Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes, 2011. 60(11): p. 2903-13. 8.Mancusi, A., et al., CD4...
1、Aministration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 2、Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancr...
Gao et al. focused on SNPs within enhancers of PB Treg cells from Type 1 diabetes patients, and in line with our data showed, that cell cycle and apoptosis regulation is highly reflected in the enhancer landscape of these patients. These data further underscore the need for additional studies...
3、Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes. 4、Type 1 diabetes immunotherapy using polyclonal regulatory T cells. 5、Administration of CD4+CD25highCD127-FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study ...
autoimmune therapy,all in one hand The largest, most advanced pipeline of cell therapies for autoimmune disease. Company deck About PolTREG Three clinical assets that will deliver value and milestones PTG007, a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis Leading ...
[28]Mcclymont S A, Putnam A L, Lee M R, et al. Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes[J]. Journal of Immunology,2011,186(7):3918-3926. [29]Christian K, Chun-Wei L, Kristina T, et al. IFN-γ production by allogeneic Foxp3...
Foxp3+ regulatory T (Treg) cells are critical contributors to the establishment and maintenance of immunological self-tolerance. Autoimmune type 1 diabetes